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Abstract
 
CD4
 
 
 
CD25
 
 
 
 regulatory T cells contribute to the maintenance of peripheral tolerance by active
suppression because their deletion causes spontaneous autoimmune diseases in mice. Human
CD4
 
 
 
 regulatory T cells expressing high levels of CD25 are suppressive in vitro and mimic the
activity of murine CD4
 
 
 
CD25
 
 
 
 regulatory T cells. Multiple sclerosis (MS) is an inflammatory
disease thought to be mediated by T cells recognizing myelin protein peptides. We hypothe-
sized that altered functions of CD4
 
 
 
CD25
 
hi
 
 regulatory T cells play a role in the breakdown of
immunologic self-tolerance in patients with MS. Here, we report a significant decrease in the
effector function of CD4
 
 
 
CD25
 
hi
 
 regulatory T cells from peripheral blood of patients with MS
as compared with healthy donors. Differences were also apparent in single cell cloning experiments
in which the cloning frequency of CD4
 
 
 
CD25
 
hi
 
 T cells was significantly reduced in patients
as compared with normal controls. These data are the first to demonstrate alterations of
CD4
 
 
 
CD25
 
hi
 
 regulatory T cell function in patients with MS.
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Introduction
 
Clonal deletion of self-reactive T cells in the thymus
and induction of T cell anergy do not alone explain the
maintenance of immunologic self-tolerance, as potentially
pathogenic auto-reactive T cells are present in the periphery
of healthy individuals (1, 2). Thus, other regulatory mech-
anisms exist to prevent autoreactive T cells from causing
immune disorders. Active suppression by regulatory T
cells plays a key role in the control of self-antigen–reactive
T cells and the induction of peripheral tolerance in vivo
(3, 4). Seminal experiments performed by Sakaguchi et al.
have shown that depletion of CD4
 
 
 
CD25
 
 
 
 suppressor
cells results in the onset of systemic autoimmune diseases
in mice (5). Furthermore, cotransfer of these cells with
CD4
 
 
 
CD25
 
 
 
 cells prevents the development of experi-
mentally induced autoimmune diseases such as coli-
tis, gastritis, insulin-dependent autoimmune diabetes, and
thyroiditis (6–10). We and others have recently described
a population of CD4
 
 
 
CD25
 
hi
 
 regulatory T cells in human
peripheral blood and thymus (11–13). Human CD4
 
 
 
CD25
 
hi
 
T cells, similar to the mouse CD4
 
 
 
CD25
 
 
 
 suppressor
cells, are anergic to in vitro antigenic stimulation and
strongly suppress the proliferation of responder T cells
upon coculture (14). CD4
 
 
 
CD25
 
 
 
 T cells are among the
best-characterized immunoregulatory subsets shown to pre-
vent activation and effector function of activated responder
T cells (15).
Multiple sclerosis (MS) is a chronic inflammatory disease
characterized by lymphocyte infiltration and inflammation
of the central nervous system (CNS) white matter. T cells
recognizing myelin protein peptides are likely involved in
the pathogenesis of the disease (16–18). Although autore-
active T cells are present in healthy individuals and patients
with autoimmune disorders, autoreactive T cells found in
patients with autoimmune disease are more easily acti-
vated as compared with those from normal subjects (19–
22). This finding led us to hypothesize that either deficient
generation or reduced effector function of CD4
 
 
 
CD25
 
hi
 
T cells play a role in regulating the autoimmune response
in patients with MS. Thus, we compared the frequency
and function of CD4
 
 
 
CD25
 
hi
 
 T regulatory cells derived
from a group of untreated patients who have relapsing/
remitting (RR) MS with those from age matched healthy
control subjects.
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Materials and Methods
 
Subjects.
 
We enrolled 15 patients in this study with definite
MS upon informed consent. This work was approved by the In-
stitutional Review Board at the Brigham and Women’s Hospi-
tal. The patients were between the ages of 25 and 57 yr, and all
had RR disease with Kurtzke Expanded Disability Status Scale
scores between 0 and 2.5. Patients were not treated with any im-
munomodulatory drugs and did not receive corticosteroids
within 3 mo of study entry. 21 normal healthy donors between
the ages of 24 and 57 yr and with no history of autoimmune dis-
eases were also enrolled in the study. Three healthy subjects be-
tween the ages of 20–30 received the influenza virus vaccina-
tion, and blood was drawn at the time points outlined in the
Results section.
 
Cell Culture Reagents.
 
Cells were cultured in RPMI 1640
medium supplemented with 5 mM Hepes, 2 nM 
 
l
 
-glutamine,
100 U/ml penicillin, 100 
 
 
 
g/ml streptomycin (BioWhittaker),
0.5 mM sodium pyruvate, 0.05 mM of nonessential amino acids
(GIBCO BRL), and 5% human AB serum (Omega Scientific
Inc.) in U-bottom 96-well plates (CoStar).
 
Cell Purification.
 
Human CD4
 
 
 
CD25
 
hi
 
 and CD4
 
 
 
CD25
 
 
 
 T
cells were separated on a FACSVantage™ SE (BD Biosciences) cell
sorter. PBMCs were isolated by Ficoll-Paque (Amersham Bio-
sciences) gradient centrifugation. Approximately 2 
 
 
 
 10
 
8
 
 cells for
each experiment were incubated for 1 h in the culture medium,
with 300 
 
 
 
l anti–CD4-CyChrome (cat. no. 555348, IgG1; BD
Biosciences), anti–CD25-PE (cat. no. IM0479, IgG2a; Immuno-
tech), and a cocktail of anti-CD14 (cat. no. 30544X, IgG2a), anti-
CD32 (cat. no. 30934X, IgG2b), and 20 
 
 
 
l anti-CD116 (cat. no.
18774B, IgM), all FITC labeled (BD Biosciences). Control
PBMCs (10
 
6
 
 cells each) were also stained with the aforemen-
tioned antibodies in combination with different mouse IgGs
(IgG2a PE-labeled cat. no. 55574; IgG1 CyChrome-labeled cat.
no. 555750; IgG1 FITC-labeled cat. no. 555748; IgG2a FITC-
labeled cat. no. 555573, and IgG2b FITC-labeled cat. no. 555742;
all purchased from BD Biosciences). Lymphocytes were washed
and sorted according to their forward and side scatter properties,
excluding large activated cells. T cell–depleted accessory cells were
obtained by negative selection of PBMCs incubated with anti-
CD2–coated beads (111.13; Dynal) and irradiated at 3,300 rad.
Figure 1. Human CD4 CD25hi T cells mediate
suppression of CD4 CD25  responder cell proliferation.
(A) The regulatory properties of CD4 CD25hi T cells
were examined from 21 healthy individuals or (B) from
15 patients with RR MS. CD4 CD25  responder ( )
and CD4 CD25hi suppressor ( ) cells (2.5   103 cells/
well) were stimulated with plate-bound anti-CD3 (0.1
and 0.5  g/ml). CD4 CD25  T cells were cocultured
with CD4 CD25hi T cells at a 1:1 ratio ( ). T cell–
proliferative responses are expressed as the mean   SE
of triplicate cultures. Culture supernatants were diluted
and analyzed to determine the cytokine profile. In the
series of experiments shown on the left, cytokine secre-
tion was not measurable. In the subsequent series,
IFN  and IL-10 were detected; their values, representing
the mean   SE of triplicate cultures, are expressed as
ng/ml. 
Viglietta et al.
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Proliferation Assay.
 
CD4
 
 
 
CD25
 
 
 
 (responders) and CD4
 
 
 
CD25
 
hi
 
 (suppressors) T cells (2.5 
 
 
 
 10
 
3 
 
cells/well) were stimu-
lated with plate-bound anti-CD3 (clone UCHT1; BD Bio-
sciences) used at three different concentrations (0.1, 0.5, and
2.5 
 
 
 
g/ml, coated in PBS for 2–4 h at 37
 
 
 
C), or soluble anti-
CD3 (clone HIT3a at 5 
 
 
 
g/ml) together with soluble anti-
CD28 (clone 28.2 at 5 
 
 
 
g/ml) in U-bottom 96-well plates.
CD4
 
 
 
CD25
 
 
 
 T cells were also cocultured with decreasing num-
bers of CD4
 
 
 
CD25
 
hi
 
 T cells (responder/suppressor ratios: 1:1,
1:1/2, 1:1/4, and 1:1/8). All cells were cultured in a final volume
of 200 
 
 
 
l in the presence of 10
 
4
 
 T cell–depleted accessory cells/
well. After 5 d of culture, 100 
 
 
 
l of supernatant was removed
from each well and used for cytokine detection, and 1 
 
 
 
Ci
[
 
3
 
H]thymidine (NEN Life Science Products) was added to each
well. The cells were harvested after 16 h; cpm/well was deter-
mined by scintillation counting (PerkinElmer). Mixing experi-
ments were performed in the presence of fixed accessory cells au-
tologous to the CD4
 
 
 
CD25
 
 
 
 responder T cells.
 
Measurement of Cytokine Level.
 
The supernatants removed
from each well before [
 
3
 
H]thymidine addition were diluted and
analyzed to determine the cytokine profile by ELISA using Im-
mulon 4 ELISA plates (Dynex Technologies). Antibody pairs
and standards for IFN
 
 
 
 were purchased from Endogen. Abs for
IL-13 and IL-10 were purchased from BD Biosciences. Avidin–
peroxidase conjugate (Sigma-Aldrich) and tetramethylbenzidine
peroxidase substrate (Kirkegaard and Perry Laboratories) were
used to develop the assay. For IL-6 detection, the Human In-
flammatory Cytometric Bead Array kit obtained from BD Bio-
sciences was used.
 
Generation of CD4
 
 
 
CD25
 
hi
 
 Clones.
 
PBMCs were stained
with the aforementioned antibodies for flow cytometry. The
CD4
 
 
 
CD25
 
hi
 
 and CD4
 
 
 
CD25
 
 
 
 cells were single cell sorted
into 96-well plates. The cells were stimulated (modification of
method described by Levings et al.; reference 23) with PHA
(Boehringer) at 0.05 
 
 
 
g/ml, autologous PBMCs (6,000 rad) were
stimulated at 3 
 
 
 
 10
 
4
 
 cells/well, JY cells (10,000 rad) were stim-
ulated at 10
 
4 
 
cells/well, and IL-2 (Teceleukin; National Cancer
Institute) were stimulated at 100 U/ml. Half the medium was re-
placed at day 7, and every 3–4 d thereafter it was replaced with
fresh medium containing 100 U/ml IL-2. The cultures were re-
stimulated with 0.05 
 
 
 
g/ml PHA, a mixture of irradiated autolo-
gous (1–3 
 
 
 
 10
 
4
 
 cells/well) and allogeneic (1–3 
 
 
 
 10
 
4
 
 cells/well)
PBMCs, and 100 U/ml IL-2. After 2–3 wk, growing clones were
tested for regulatory activity as defined by suppression of cocul-
tured anti-CD3–mediated T cell proliferation and the cloned cell
dependence on exogenous IL-2 for proliferation. With these ex-
periments, we further confirmed the data from Levings et al.
showing the possibility of single cell cloning of CD4
 
 
 
CD25
 
hi
 
regulatory cells. Clones were analyzed in cocultures containing
4 
 
 
 
 10
 
3
 
 autologous CD4
 
 
 
CD25
 
 
 
 T cells or 4 
 
 
 
 10
 
3
 
 PBMCs/well
and 2 
 
 
 
 10
 
3
 
 cloned cells/well. Stimulation was provided by the
addition of magnetic beads with covalently attached anti-CD3
(UCHT1, bound to tosyl-activated magnetic beads at 1 
 
 
 
g/10
 
7
 
beads; Dynal Biotech Inc.). The beads were added to the cultures
at 1.5 
 
 
 
 10
 
4
 
 cells/well. 
 
3
 
[H]Thymidine was added to the cultures
after 4 d of stimulation. Percent suppression was determined as
1 
 
 
 
 (cpm incorporated in the coculture)/cpm of responder pop-
ulation alone)   100%.
Figure 1 (continued)Loss of CD4+CD25+ Regulatory T Cell Function in Human Autoimmune Disease 974
Statistical Analysis. The mean   SE thymidine uptake and cy-
tokine secretion of triplicate cultures was calculated for each ex-
perimental condition. The response of CD4 CD25  T cells were
normalized to 100 to calculate the percent suppression resulting
from the addition of CD4 CD25hi to the cultures. The Mann-
Whitney test was used to evaluate possible differences in the
CD4 CD25hi function between patients with MS and healthy do-
nors. The number of wells that produced growth from the clon-
ing of cells derived from patients with MS and healthy controls
was compared using hierarchical logistic regression analysis.
Results
CD4 CD25hi T Cells Are Present with the Same Frequency
in Healthy Donors and Patients with MS. We stained whole
mononuclear cells from freshly drawn human blood
with different combination of anti-CD4–CyChrome, anti-
CD25–PE, and a cocktail of FITC-labeled anti-CD14,
anti-CD32, and anti-CD116 antibodies. The cells were
gated on lymphocytes via their forward and side scatter fea-
tures, and all FITC-labeled cells were negatively selected
during sorting. Human peripheral blood contains a hetero-
geneous population of CD4 CD25  T cells that express
either moderate levels of CD25 consisting of nonregulatory
T cells or high levels of CD25 that exhibit regulatory func-
tion (24). As there are no other known cell surface markers
able to identify regulatory T cells ex vivo, we used CD25
expression to discriminate regulatory T cells in humans.
We analyzed the mean fluorescent intensity of the CD25 
population in both patients with MS and control subjects
and found no differences between the two groups. Simi-
larly, no differences in the frequency of CD4 CD25hi T
cells were found between patients and healthy controls;
 10% of CD4 T cells express the  -chain of IL-2 receptor
CD25, whereas only 1–2% of the CD4 T cells are CD25hi
in both subject groups. The mean of frequency was 1.4%  
0.3 in the healthy control group and 1.2%   0.2 in the MS
patient group; no statistically significant differences were
found between the two populations (P   0.21).
CD4 CD25hi Regulatory T Cells Display Impaired Function
in Patients with MS. Because it was critical to examine
the regulatory T cell function, we isolated highly pure
CD4 CD25hi regulatory and CD4 CD25  responder cell
populations by high speed flow cytometric sorting. CD4 
CD25  responder cells from both patients with MS and
healthy individuals responded similarly in a dose-dependent
fashion to varying concentration of plate-bound anti-CD3
mAb. CD4 CD25hi T cells isolated from both groups were
anergic to stimulation at all doses of plate-bound anti-CD3,
indicating that CD4 CD25hi T cells isolated from patients
with MS do exhibit this regulatory property.
To quantitate their regulatory function, CD4 CD25hi T
cells were cocultured with autologous responder cells (2.5  
103 cells/well) at different ratios (responder/suppressor
ratios: 1:1, 1:1/2, 1:1/4, and 1:1/8). As reported previously
in healthy individuals, CD4 CD25hi T cells consistently
suppressed proliferation at a 1:1 ratio (Figs. 1 A and 2). In-
creasing the ratio of responder/suppressor T cells resulted
in less suppression (Fig. 2). In striking contrast, the regula-
tory CD4 CD25hi T cells isolated from the circulation
of patients with MS (while similar in frequency as com-
pared with healthy controls) poorly inhibited responder
CD4 CD25  T cell proliferation (Figs. 1 B and 2). Be-
cause we have shown previously that increased strength of
signal inhibits regulation (24), we stimulated cocultures of
regulatory and responder T cells from patients with MS and
healthy controls with a maximal concentration (2.5  g/ml)
of plate-bound anti-CD3 mAb. As predicted, the CD4 
CD25hi regulatory T cells no longer suppressed the prolif-
eration of responder T cells (Fig. 2).
We also examined the production of cytokines in all
the cultures and the ability to inhibit their secretion by
CD4 CD25hi T cells cocultured with CD4 CD25  re-
sponder cells. The secretion of the Th1 cytokine IFN , as
would result from the activation of destructive, autoreactive
T cells, was suppressed in CD4 CD25hi T cell cocultures
from healthy controls, but not in cocultures derived from pa-
tients with MS (Fig. 1, A and B). Because there was no de-
tectable secretion of IL-13 at the cell numbers used in these
experiments, those data are unpublished. IL-10 was variably
secreted, predominantly by the CD4 CD25  T cells. The
secretion of IL-10 was often reduced upon coculture with
CD4 CD25hi T cells, excluding a potential role of this cyto-
kine in mediating this regulatory suppressor function (Fig. 1,
A and B). In this ex vivo model of suppression, blocking IL-
Figure 2. Summary of
CD4 CD25hi T cell regulatory
function that is altered in patients
with MS. The mean percent inhi-
bition of the proliferative response
by CD4 CD25hi cells derived
from 15 MS patients ( ) and
21 healthy controls ( ) was
calculated. CD4 CD25  and
CD4 CD25hi populations were
stimulated with plate-bound
anti-CD3 mAb, alone or cocul-
tured at varying ratios. The pro-
liferative response was inhibited
upon addition of CD4 CD25hi cells to the CD4 CD25  responder cells at a 1:1 ratio in normal controls. Regulatory T cells from patients with MS
exhibited significantly less suppressor activity. Decreasing the number of CD4 CD25hi T cells (responder/suppressor ratios: 1:1/2 and 1:1/4) resulted in
less suppression in all the conditions examined.Viglietta et al. 975
10 or TGF  does not result in loss of suppressor function by
CD4 CD25  regulatory T cells (unpublished data).
Recent studies have shown that the presence of IL-6 can
contribute to the loss of CD4 CD25  suppression (25).
We measured the levels of IL-6 secretion in the cultures of
five healthy individuals and four patients with MS to inves-
tigate its potential role in the lack of suppression observed
with patient-derived cells. We found that IL-6 levels did
not correlate with the presence or absence of CD4 CD25hi
T cell–mediated suppression.
It was also important to examine whether the loss of reg-
ulatory function was due to a decrease in CD4 CD25hi T
cell function or an increase in the resistance of activated
CD4 CD25  responder T cells to inhibition. Thus, we
performed mixing experiments in which patient and con-
trol regulatory CD4 CD25hi T cells were cocultured with
the autologous and the converse target cells isolated from
either healthy subjects or patients with MS. Regulatory T
cells from patients with MS could not suppress the prolifer-
ative response of target responder T cells from either pa-
tients or healthy controls (suppression  23%). In contrast,
in the reciprocal experiments, regulatory CD4 CD25hi T
cells from healthy controls suppressed the proliferative re-
sponse of target CD4 CD25  T cells derived from both
controls and patients with MS (suppression  78%; Fig. 3).
These data indicate that the primary regulatory defect is in
the function of CD4 CD25hi T cells isolated from the cir-
culation of patients with MS.
CD62L Expression on CD4 CD25hi Regulatory T Cells.
Although there were no differences in the frequency of
CD4 CD25hi T cells or in their proliferation or cytokine
secretion in response to different stimuli between healthy
subjects and patients with MS, it was important to deter-
mine whether an increase in the frequency of activated
CD4  T cells in the circulation of patients with MS may be
diluting the regulatory CD4 CD25hi T cells. Therefore,
we further restricted the isolation of T regulatory cells by
sorting only those CD4 CD25hi T cells that expressed
CD62L because L-selectin expression is down-regulated
upon activation. We isolated CD4 CD25hiCD62L  and
total CD4 CD25hi regulatory T cells from healthy subjects
and patients with MS and found that, whereas in the
healthy controls both populations were able to suppress the
proliferative response to anti-CD3 stimulation, neither
population of regulatory cells isolated from patients with
MS was able to inhibit the proliferation of the CD4 
CD25  responder population (Fig. 4). The fact that the
CD4 CD25hiCD62L  T cells isolated from patients are
depleted of the potentially activated CD62L  T cells yet
still unable to suppress indicates that the impaired regula-
tory T cell function in patients with MS is not due to con-
tamination by activated T cells.
In Vivo Immunization Did Not Alter CD4 CD25hi Regula-
tory T Cell Function. To further rule out the possibility
that impaired suppressive function observed in patients
with MS was due to an increase in the frequency of acti-
vated CD4  T cells in the circulation or due to an altered
activation state of the responder cells, we examined the
Figure 3. CD4 CD25hi T cells from patients with MS do not inhibit
proliferation of responder T cells isolated from either the autologous
individual or healthy donors. CD4 CD25  responder T cells and
CD4 CD25hi cells from MS patients and normal controls were stimulated
with plate-bound anti-CD3 at 0.5  g/ml. 2.5   103 cells/well responder T
cells from MS patients were cocultured with the same number of autologous
CD4 CD25hi regulatory T cells (1st bar) or with regulatory cells isolated
from healthy donors (2nd bar). Conversely, responder T cells from
healthy donors were cocultured either with CD4 CD25hi cells derived
from the same subject (3rd bar), or with regulatory cells isolated from
patients with MS (4th bar).
Figure 4. The CD62L  subset of CD4 CD25hi
regulatory T cells exhibits decreased suppressive function
in patients with MS. CD4 CD25hiCD62L  T cells
were isolated from seven healthy individuals (left) and
three patients with MS (right). Each symbol is repre-
sentative of a different individual. Total CD4 CD25hi
T cells were also isolated from four out of seven
healthy subjects and two out of three patients. The
percent suppression of coculture proliferation in re-
sponse to plate-bound anti-CD3 was calculated in
each individual. The CD4 CD25hi regulatory T cells
derived from healthy controls were able to induce
strong inhibition of the proliferative response (55–97%
suppression) as shown previously. The CD62L  subset
of CD4 CD25hi T cells derived from the same individuals exhibit enhanced suppressive capacity. In contrast, the regulatory cells derived from patients,
although depleted of CD62L  activated T cells, show decreased inhibitory function (4–29% suppression) as compared with the suppression observed in
healthy individuals.Loss of CD4+CD25+ Regulatory T Cell Function in Human Autoimmune Disease 976
regulatory function of CD4 CD25hi T cells derived from
healthy subjects recently immunized with the influenza vi-
rus vaccine. The regulatory T cells from three subjects ex-
amined after vaccination showed intact suppressive ability
(93, 84, and 65% suppression of proliferation). One indi-
vidual was examined both before and after vaccination and
demonstrated no differences in the suppressive ability (68%
suppression before and 65% after vaccination). These data
provide evidence that an ongoing immune response does
not affect the intrinsic ability of CD4 CD25hi regulatory T
cells to function.
CD4 CD25hi Regulatory T Cells in Other Autoimmune
Diseases. We examined the regulatory activity of CD4 
CD25hi T cells isolated from a small series of patients with
other autoimmune diseases to confirm our hypothesis that
the changes in function of these regulatory CD4 CD25hi T
cells would not be specific to a single autoimmune disease.
The frequency of CD4 CD25hi T cells in this control
group was 1.4%   0.4; no differences were found between
these patients and the subjects with MS (P   0.44) or the
healthy individuals (P   0.35). The regulatory cells derived
from patients with thyroiditis and psoriasis showed reduced
suppressive capacity (7 and 19%, respectively), whereas the
regulatory activity of cells from the patients with inflam-
matory bowel disease and ankylosing spondylitis showed
strong suppressive activity (97 and 68%, respectively).
These preliminary data suggest the need for a more exten-
sive analysis of the role of the regulatory T cell subset in
other autoimmune diseases and are consistent with our hy-
pothesis that dysfunctions in regulatory T cells may be
viewed as one of many risk factors in human autoimmune
disorders.
The Nature of TCR Signaling Determines Suppressor Func-
tion. We have shown previously that a qualitatively dif-
ferent stimulus, such as soluble anti-CD3 and anti-CD28,
induced lower levels of responder T cell proliferation as
compared with plate-bound anti-CD3 and, thus, was more
significantly inhibited upon coculture with CD4 CD25hi.
It was of interest to examine whether differences in sup-
pressor function by CD4 CD25hi cells between patients
with MS and control subjects would be observed with
qualitative changes in TCR signaling. Cocultures of regu-
latory and responder T cells from patients and controls
were stimulated with soluble anti-CD3 and anti-CD28. As
expected, the magnitude of the proliferative response was
significantly lower than that obtained with plate-bound
anti-CD3 from the same individual. The CD4 CD25  T
cells isolated from patients and controls responded similarly
to this stimulus. Yet, in contrast to plate-bound anti-CD3,
the qualitatively different TCR signal delivered by soluble
anti-CD3 and anti-CD28 allowed the appearance of sup-
pressor function by cocultured CD4 CD25hi regulatory T
cells derived from patients with MS, particularly at higher
ratio of regulatory T cells in the culture (Fig. 5).
Figure 6. Reduced ability to generate CD4 CD25hi clones from blood
of MS patients. (A) CD4 CD25hi or CD4 CD25  T cells from patients
with MS and healthy controls were cloned as described in Materials and
Methods. The difference in the cloning frequency of the regulatory
CD4 CD25hi cells between patients with MS and healthy subjects was
highly significant (P   0.0001), whereas the ability to generate clones
from CD4 CD25  cells was not different (P   0.21). (B) T cell clones
were tested for dependency on exogenous IL-2 by stimulation with anti-
CD3 beads   IL-2 (data are presented as stimulation indices). The same
clones were also tested for their ability to inhibit the proliferation of cocul-
tured responder T cells upon stimulation with anti-CD3 beads. The three
representative CD4 CD25hi clones (a–c) shown suppress the proliferation
of autologous CD4 CD25  T cells, whereas a T cell clone (d) representing
a minor population of the clones derived from the CD4 CD25hi population
is shown, and all of the CD4 CD25  clones (e) did not inhibit proliferation
of cocultured T cells.
Figure 5. The proliferative response in both patients and healthy controls
is suppressed in cultures receiving T cell receptor signals of different natures.
CD4 CD25  responder T cells and CD4 CD25hi cells from six MS
patients and six normal controls were stimulated with soluble anti-CD3
and anti-CD28 (5  g/ml) alone or cocultured at different responder/
suppressor ratios (1:1, 1:1/2, and 1:1/4). The average proliferative response
was 13,494 cpm in the patient group and 15,974 cpm in the control
group. The percent inhibition of coculture proliferation was calculated in
patients with MS ( ) and healthy controls ( ).Viglietta et al. 977
Low CD4 CD25hi Cloning Frequency in Patients with MS.
To examine potential mechanisms for the loss of reg-
ulatory T cell function, we directly single cell sorted
CD4 CD25hi and CD4 CD25  cells from patients
and  healthy subjects and analyzed their frequency and
functional activity. Although the cloning frequency of
CD4 CD25  T cells was similar in patients with MS and
control subjects, the cloning frequency of CD4 CD25hi
cells was significantly lower in patients with MS as com-
pared with normal control subjects (Fig. 6 A). Due to the
slow growth of the clones, we tested their regulatory ac-
tivity after a second round of PHA/IL-2 stimulation. We
examined IL-2–dependent TCR-mediated proliferation
and inhibition of T cell proliferation as two major charac-
teristics of regulatory T cells (Fig. 6 B). By these criteria,
60% of the CD4 CD25hi clones generated from healthy
controls and 17% of the clones derived from patients with
MS exhibited regulatory activity.
Discussion
It has become clear that defects in different populations
of regulatory T cells contribute to the induction of autoim-
mune diseases in animal models. Here, we examined
whether a similar defect in regulatory CD4 CD25hi T cells
occurs in humans with MS. We observed a significant re-
duction in the effector functions of this regulatory T cell
population in subjects with MS compared with healthy do-
nors. These data are among the first clear demonstrations of
the functional defect in CD4 CD25hi regulatory T cells in
a human autoimmune disease.
An important aspect of these investigations was the mea-
surement of regulatory T cell function as opposed to simple
phenotypic measurement of CD4 CD25  T cell fre-
quency. Unlike 6-wk-old mice raised in clean facilities,
whose total CD4 CD25  T cell population manifests
regulatory properties, humans are exposed to myriad
infections and show a significant population of CD4 
CD25medium/low T cells that do not exhibit regulatory func-
tion (24). Thus, it was critical to examine the functional
state of the regulatory T cells expressing high levels of
CD25. We have demonstrated previously that the strength
of signal delivered through the TCR of target T cells is
one factor determining whether regulatory CD4 CD25hi
T cells can suppress the responder T cell proliferation
(24). Thus, to properly examine the function of regulatory
CD4 CD25hi T cells, we used several different strengths of
stimulatory signals in these experiments. We observed that
the strong signal provided by maximal concentration of
plate-bound anti-CD3 mAb similarly abrogated suppres-
sion in both patient and control cocultures. In contrast,
lower concentrations of plate-bound anti-CD3 delivered a
signal that resulted in the appearance of a significant defect
in the suppressive function of this subset of regulatory cells
derived from patients with MS.
The use of different stimulatory conditions allowed us to
reveal alterations in the regulatory function of CD4 CD25hi
T cells while still demonstrating that they are CD25  regu-
latory T cells as opposed to activated responder cells ex-
pressing CD25. Stimulation of cultures with soluble anti-
CD3 and anti-CD28, which have previously shown to be
the most permissive for enabling coculture suppression, gave
equivalent levels of suppression in patients and control sub-
jects when cocultured at 1:1 ratios. In contrast, the stimula-
tion provided by plate-bound anti-CD3 at 0.1 and 0.5  g/
ml resulted in a threefold decrease of suppression by
CD4 CD25hi cells derived from patients with MS as com-
pared with normal controls. Previous experiments showed
that delivering qualitatively different T cell receptor signals
to responder T cells, such as that provided by self-antigens
as compared with microbial antigens, results in a greater
sensitivity to suppression. Thus, the present findings may
help explain defects in suppression of autoreactive T cells in
autoimmune patients as compared with T cells stimulated
by microbial antigens during infections.
Because it was of interest to examine the regulatory
function of CD4 CD25high T regulatory cells in an anti-
gen-specific system, we attempted to induce antigen-spe-
cific responses to myelin basic protein (MBP) in this in
vitro system. However, as expected with the low frequency
of MBP-specific CD4 CD25  effector T cells and the low
number of CD4 CD25high T regulatory cells that can be
isolated by FACS®, it was not possible to directly measure
suppression of autoantigen-specific T cells in patients. As
the frequency of MBP-specific T cells appears to be in the
range of 1/106 cells, the majority of the effector T cells that
in our assay are cultured at 1–2   104 cells/well do not re-
spond to the antigen.
An important control to note in all these experiments is
the anergy or lack of thymidine incorporation resulting
from stimulation of CD4 CD25hi T cells cultured alone.
This anergy indicates that CD4 CD25hi T cells isolated
from patients with MS are not CD25 -activated T cells be-
cause such cells would not exhibit regulatory activity, but
rather enhance proliferation. It was critical to determine
whether the decrease in T cell regulatory function ob-
served in patients with MS was due to a defect in the
CD4 CD25hi T cell subset or whether the responder
CD4 CD25  T cells were refractory to suppression. By
performing comixing experiments, we could clearly dem-
onstrate that the defect lies in the CD4 CD25hi T cell
function, as opposed to enhanced responder T cell resis-
tance in patients with MS.
In mice thymectomized on day 3 of life, a spontaneous
autoimmune disease develops that does not involve in-
flammation in the CNS (5). This raises the question as to
whether CD4 CD25  T cells can be involved in murine
models of CNS autoimmunity, reflecting the observations
made here in patients with MS. Thus, it is of interest that
in a mouse model of MS, MOG35–55-specific experimental
autoimmune encephalomyelitis, a similar population of
CD4 CD25  T cells, has been shown able to protect
from both the onset and the progression of autoimmune
demyelination induced by either active MOG35–55 immu-Loss of CD4+CD25+ Regulatory T Cell Function in Human Autoimmune Disease 978
nization or adoptive transfer of autoreactive T cells (26).
These data provide further evidence that CD4 CD25 
regulatory T cells can migrate into the CNS to mediate
immune responses.
The cell surface marker CD62L was used to further
characterize the CD4 CD25hi regulatory subset derived
from both healthy individuals and patients with MS. In
mice, the expression of this molecule on CD4 CD25  T
cells has been shown to confer a greater suppressive ability
(27, 28). We demonstrated that in healthy subjects, both
CD4 CD25hiCD62L  and total CD4 CD25hi regulatory
T cell populations exhibit similar abilities to suppress the
proliferative response with anti-CD3 stimulation. In con-
trast, the regulatory T cells isolated from patients with MS,
although expressing high levels of CD62L, were still unable
to inhibit the responder cell proliferation, thus confirming
a defect in the function of regulatory T cells derived from
patients with MS.
The relative inability to generate CD4 CD25hi clones
from patient blood may suggest a mechanism underlying
the defective regulatory T cell function. One possibility is
that CD4 CD25hi cells have undergone clonal exhaustion
in vivo in the attempt to down-modulate the ongoing au-
toimmune response in patients. Another possibility is that
their expansion is abnormally inhibited by other factors
present in the single-cell cloning cultures. We can specu-
late that altered sensitivity of these cells to stimulation
could also negatively affect their ability to exert regulatory
functions. Although other factors, such as IL-6 secretion,
may abrogate the regulatory function of CD4 CD25  T
cells, they may also adversely affect the growth of these
cells. However, because there was no correlation between
IL-6 cytokine secretion and the loss of T cell regulatory
function, alterations in IL-6 secretion in patients with MS
does not appear to be the underlying mechanism for the
loss of suppressor function by CD4 CD25hi T cells. These
and other possibilities are currently under investigation.
Although in vitro measurement of biologic function in
patients with autoimmune diseases will always be correla-
tive, these in vitro experiments, based on in vitro and in
vivo experimentation in mouse models of autoimmune
disease, provide the first definitive evidence for a defect in
regulatory T cell function in a human autoimmune dis-
ease. Ultimately, monitoring the effects of immunomodu-
latory drugs on this regulatory T cell subset will help de-
fining their pathogenic role in MS and other human
autoimmune diseases.
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